TESARO, Inc. (NASDAQ:TSRO) – Stock analysts at Leerink Swann increased their Q3 2017 earnings estimates for TESARO in a research report issued to clients and investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of ($0.56) for the quarter, up from their previous estimate of ($2.01). Leerink Swann currently has a “Market Perform” rating and a $143.00 target price on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2017 earnings at ($2.40) EPS, FY2017 earnings at ($8.32) EPS, FY2018 earnings at ($4.29) EPS, FY2019 earnings at ($0.24) EPS, FY2020 earnings at $3.62 EPS and FY2021 earnings at $5.36 EPS.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period last year, the firm posted ($1.28) EPS. TESARO’s revenue was down 17.6% on a year-over-year basis.
Other equities analysts also recently issued reports about the stock. Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the stock a “buy” rating in a research report on Monday, June 5th. Citigroup Inc. reissued a “buy” rating and set a $216.00 target price (down from $232.00) on shares of TESARO in a research report on Saturday, April 22nd. Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Monday, June 5th. Oppenheimer Holdings, Inc. set a $199.00 target price on shares of TESARO and gave the stock a “buy” rating in a research report on Sunday, June 4th. Finally, Bank of America Corporation reissued a “buy” rating and set a $154.00 target price on shares of TESARO in a research report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $176.35.
Shares of TESARO (NASDAQ TSRO) opened at 111.85 on Friday. The stock’s market cap is $6.06 billion. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The stock has a 50 day moving average price of $130.46 and a 200 day moving average price of $149.15.
Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock worth $1,237,718,000 after buying an additional 32,918 shares during the period. BlackRock Inc. increased its stake in TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after buying an additional 195,590 shares during the period. Vanguard Group Inc. increased its stake in TESARO by 2.1% in the second quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock worth $416,537,000 after buying an additional 62,104 shares during the period. State Street Corp increased its stake in TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock worth $152,617,000 after buying an additional 3,784 shares during the period. Finally, BB Biotech AG increased its stake in TESARO by 6.5% in the second quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after buying an additional 53,408 shares during the period.
In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 40.50% of the stock is owned by company insiders.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.